Compare Nano Dimension Ltd - ADR (NNDM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs TG Therapeutics Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.51 (market cap $327.47M), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 26× Nano Dimension Ltd - ADR's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | TGTX | |
|---|---|---|
Market Cap | $327.47M | $8.53B |
Sector | Technology | Health |
52-Week High | $2.14 | $59.06 |
52-Week Low | $1.21 | $26.94 |
Enterprise Value | -$77.38M | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $121M but a net loss of -$163M, reflecting a net margin of -135.18%. Recent strategic moves include appointing a new board member and cost-saving initiatives aimed at reducing cash burn by $25M annually. The balance sheet shows a strong cash position of $757.96M with minimal debt, but operating cash flow remains negative.
The outlook is cautious due to persistent losses and high cash burn, though asset sales and cost cuts may improve liquidity. Investment opportunity lies in the company's cash reserves and potential strategic shifts, but risks include ongoing operational losses and shareholder activism. The stock faces pressure from weak profitability and bearish technical trends.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
